Dr. Zhijun Yang 阳志军
Chief Physician
Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical diagnosis and treatment of cervical, ovarian, endometrial, vulvar cancers, trophoblastic tumors, and common gynecological diseases. Expertise in laparoscopic surgery and multidisciplinary care for advanced or recurrent malignancies.
Dr. Yang holds a PhD and serves as Vice President of Guangxi Medical University Cancer Hospital. A master’s and doctoral supervisor, Dr. Yang leads research funded by the National Natural Science Foundation and other grants. Publications include 5 SCI papers and 43 total academic articles. Awards include the Second Prize of Guangxi Science and Technology Progress Award.
Professional roles
- Member, Youth Committee of the 2nd Committee of the Gynecologic Oncology Branch, Chinese Medical Association
- Member, Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Vice Chair, Gynecologic Oncology Professional Committee, Guangxi Anti-Cancer Association
- Standing Council Member and Deputy Secretary-General, Guangxi Anti-Cancer Association
Name order: in Chinese the family name comes first (Yang Zhijun). Papers usually list the name as Zhijun Yang or Yang Z.
Selected publications
7 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Sci Rep, 2026 (senior author): Prognostic analysis of epithelial ovarian cancer patients with normal CA125 level: a population-based comparative study. PubMed 42331949
- Technol Cancer Res Treat, 2024 (senior author): piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer. PubMed 38706262
- Oncol Lett, 2023 (senior author): Prognostic significance of TM4SF1 and DDR1 expression in epithelial ovarian cancer. PubMed 37720676
- Int J Gen Med, 2021 (senior author): ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining. PubMed 33790626
- J Clin Pharm Ther, 2021 (senior author): Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study. PubMed 32975332
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion